XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Reportable Segments
 9 Months Ended
Sep. 30, 2017
Segment Reporting [Abstract]  
Reportable Segments
Reportable Segments
The structure of the Company’s internal organization is divided into the following reportable segments, which are also the Company’s operating segments: E&C, D&S, and BioMedical. Corporate includes operating expenses for executive management, accounting, tax, treasury, human resources, information technology, legal, internal audit, and risk management.
The following table represents information for the Company’s reportable segments and its corporate function:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Sales
 
 
 
 
 
 
 
Energy & Chemicals (1)
$
46,588

 
$
23,711

 
$
126,473

 
$
122,865

Distribution & Storage
139,281

 
126,646

 
390,057

 
363,743

BioMedical
54,662

 
53,573

 
166,309

 
158,174

Consolidated
$
240,531

 
$
203,930

 
$
682,839

 
$
644,782

Operating Income (Loss) (1) (2) (3) (4)
 
 
 
 
 
 
 
Energy & Chemicals
$
329

 
$
(5,736
)
 
$
(2,420
)
 
$
14,190

Distribution & Storage
21,016

 
14,715

 
49,186

 
37,550

BioMedical
9,539

 
20,916

 
24,387

 
38,120

Corporate (4)
(20,436
)
 
(9,831
)
 
(50,523
)
 
(34,820
)
Consolidated
$
10,448

 
$
20,064

 
$
20,630

 
$
55,040


___________
(1) 
Includes results from the Hudson and Hetsco acquisitions, which are included in the Company’s E&C segment. Refer to the Business Combinations note for further details.
(2) 
During the third quarter of 2016, the Company recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep Corporation under the related representation and warranty insurance.  For the three months ended September 30, 2016, this reduced our BioMedical segment’s cost of sales by $15,145 and Corporate SG&A expenses by $859, net of associated legal fees.  For the nine months ended September 30, 2016, this reduced our BioMedical segment’s cost of sales by $15,145 and Corporate SG&A expenses by $376, net of associated legal fees recorded in the first nine months of 2016.
(3) 
Includes restructuring costs of $2,749 and $305 for the three months ended September 30, 2017 and 2016, respectively, and $12,417 and $6,303 for the nine months ended September 30, 2017 and 2016 respectively.
(4) 
Includes acquisition-related costs of $7,445 and $8,587 for the three and nine months ended September 30, 2017, respectively.
The following table represents total assets for the Company’s reportable segments and its corporate function:
 
September 30, 2017
 
December 31, 2016
Total Assets
 
 
 
Energy & Chemicals (1)
$
782,553

 
$
172,494

Distribution & Storage
679,350

 
631,715

BioMedical
165,195

 
166,940

Corporate
65,925

 
261,933

Consolidated
$
1,693,023

 
$
1,233,082

___________
(1) 
Includes assets acquired from the Hudson and Hetsco acquisitions, which are included in the Company’s E&C segment. Refer to the Business Combinations note for further details.